Abstract
Women with a life expectancy ≥10 years and no diagnosis/history of breast cancer who are considered to be at increased risk for breast cancer should receive counseling to decrease breast cancer risk, considering lifestyle factors, therapy with risk reduction agents, and risk reduction surgery (in BRCA1/2 mutation carriers).Bilateral risk-reducing mastectomy decreases the risk of developing breast cancer by at least 90%; it should be proposed to carefully selected women at high risk for breast cancer considering BRCA1/2 or other genetic mutations and previous history of LCIS. In current practice, atypical hyperplasia is not an indication for prophylactic mastectomy.Bilateral risk-reducing salpingo-oophorectomy decreases the risk of developing ovarian and fallopian cancer by 85–95% and breast cancer by 50% in BRCA1/2 mutation carriers when performed in premenopausal age. Peritoneal washing should be performed at surgery, and pathologic assessment should include fine sectioning of the ovaries and fallopian tubes. The additional benefit of concurrent hysterectomy is not clear at the time. In women with no personal history of breast cancer, short-term HRT use does not negate the protective effect of RRSO on subsequent breast cancer risk, and it should be offered until the time of expected natural menopause.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antoniou A, Pharoah P, Narod S, Risch HA et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130
NCCN Guidelines 1 (16 Dec 2016) Breast cancer risk reduction
Gail MH, Costantino JP (2001) Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst 93(5):334–335
Hartmann LC et al (2015) Atypical hyperplasia of the breast, risk assessment and management options. N Engl J Med 372:78–89
Hartmann LC, Radisky DC, Frost MH et al (2014) Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila) 7:211–217
Hartmann LC et al (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77–84
Giuliano AE, Boolbol S, Degnim A et al (2007) Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Ann Surg Oncol 14(9):2425–2427
Giuliano AE, Boolbol S, Degnim A, Henry K, Marilyn Leitch A, Morrow M (2007) Annals of. Surg Oncol 14(9):2425–2427. doi:10.1245/s10434-007-9447-z
Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80–87
Kauff ND, Domchek SM, Friebel ME et al (2008) Risk-reducing salpingooophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26:1331–1337
Eisen A, Lubinski J, Klijn J et al (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23:7491–7496
Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616–1622
RIGENIO Guidelines (2007) Regione Piemonte
Finch A, Beiner M, Lubinski J et al (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296:185–192
Lavie O, Hornreich G, Ben-Arie A, Rennert G, Cohen Y et al (2004) BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 92:521–524
Finch A, Shaw P, Rosen B et al (2006) Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 100:58–64
Colgan TJ, Boerner SL, Murphy J, Cole DE, Narod S, Rosen B (2002) Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol 85(3):397–403
Kwon JS, Tinker A, Pansegrau G et al (2013) Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA. Obstet Gynecol 121:14–24
Cibula D, Widschwendter M, Májek O, Dusek L (2011) Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 17(1):55–67
Finch A, Metcalfe KA, Chiang JK, Elit L, McLaughlin J, Springate C et al (2011) The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 121(1):163–168
Cohen JV, Chiel L, Boghossian L, Jones M, Domchek SM et al (2012) Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Familial Cancer 11(1):69–75
Shukla PC, Singh KK, Quan A et al (2011) BRCA1 is an essential regulator of heart function and survival following myocardial infarction. Nat Commun 2:593
Rebbeck TR, Friebel T, Wagner T et al (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23:7804–7810
Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT et al (2008) Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 100(19):1361–1367
Marchetti C, Iadarola R, Palaia I, di Donato V, Perniola G, Muzii L, Panici PB (2014) Hormone therapy in oophorectomized BRCA1/2 mutation carriers. Menopause 21(7):763–768
International Menopause Society (IMS) (2013) Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 16:316–337
Von Schoultz E, Rutqvist LE, Stockholm Breast Cancer Study Group (2005) Menopausal hormone replacement therapy after breast cancer: the Stockholm randomised trial. J Natl Cancer Inst 97:533–535
Holmberg L, Anderson H (2004) For the HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet 363:453–455
Holmberg L, Iversen OE, Rudenstam CM et al (2008) Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100:475–482
Fahlén M, Fornander T, Johansson H et al (2013) Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 49(1):52–59
Kenemans P, Bundred NJ, Foidart JM et al (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a doubleblind, randomised, non-inferiority trial. Lancet Oncol 10:135–146
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 International Society of Gynecological Endocrinology
About this chapter
Cite this chapter
Sismondi, P. et al. (2018). Risk-Reducing Surgery and Treatment of Menopausal Symptoms in BRCA Mutation Carriers (and Other Risk Women). In: Birkhaeuser, M., Genazzani, A. (eds) Pre-Menopause, Menopause and Beyond. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-319-63540-8_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-63540-8_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-63539-2
Online ISBN: 978-3-319-63540-8
eBook Packages: MedicineMedicine (R0)